Cereno Scientific will engage in in-person one-on-one meetings with US and international investors and financial-market participants during the conference. A company presentation has been recorded in advance and will be available virtually through the conference platform and Cereno Scientific’s website in connection with the conference.

The event forms part of Cereno’s ongoing international investor relations activities aimed at broadening awareness of the Company, expanding engagement with new investor audiences and, over time, strengthening and diversifying its shareholder base.

Cereno enters the conference at an important stage of clinical development, with multiple potential value drivers across its pipeline. The global Phase IIb EPIMODE trial of lead drug candidate CS1 in pulmonary arterial hypertension (PAH) is underway and screening patients, while CS014 is approaching topline results from its FDA-aligned Phase I pharmacokinetic (PK) bridging study, anticipated in Q3 2026. Together, Cereno’s two clinical-stage HDAC inhibitor programs provide a differentiated approach based on epigenetic modulation, targeting underlying mechanisms of disease progression in rare cardiovascular and pulmonary diseases.

“Expanding our engagement with US and international investors is an important part of building Cereno for its next stage of development. We are introducing the Company to new investor audiences at a time when our pipeline is becoming increasingly mature, with EPIMODE in active clinical execution and CS014 approaching an important near-term readout. This gives us a strong and increasingly tangible investment case to communicate. Our participation at H.C. Wainwright builds on the international investor activities we have undertaken during the year as we work to broaden understanding of Cereno and, over time, strengthen and diversify our shareholder base,” said Sten R. Sörensen, CEO of Cereno Scientific.

The recorded presentation will provide an update on Cereno Scientific’s pipeline and development strategy, including the ongoing Phase IIb EPIMODE trial of CS1 in PAH and the advancement of CS014 toward Phase IIb development in pulmonary hypertension associated with interstitial lung disease (PH-ILD). It will also highlight upcoming milestones and the broader value potential of Cereno’s pipeline.

The H.C. Wainwright Annual Global Investment Conference brings together public companies, institutional investors, private equity and venture capital firms, industry executives and other financial-market participants for company presentations, one-on-one meetings and networking.

Meeting opportunities

Sten R. Sörensen will be available for in-person one-on-one meetings during the conference. To request a meeting with Cereno Scientific, please contact ir@cerenoscientific.com. Registered conference participants can also request meetings through the conference’s meeting-booking platform.

For more information about the conference and registration, please visit www.hcwevents.com/annualconference.